Markets JBS

JBS (JBS) Q3 2026 Earnings Call Transcript

Logo of jester cap with thought bubble.

Image source: The Motley Fool.

DATE

Tuesday, Nov. 10, 2026

CALL PARTICIPANTS

  • Global CEO of JBS - Gilberto Tomazoni
  • Global CFO of JBS - Guilherme Cavalcanti
  • CEO of JBS USA - Wesley Batista Filho
  • Investor Relations Director - Christiane Assis

TAKEAWAYS

  • Net Sales -- $22.7 billion, representing 1% growth compared to the prior year driven by increased volumes in certain segments despite pricing pressure in others.
  • Adjusted EBITDA (IFRS) -- $1.2 billion, reflecting a margin of 5.2% during a quarter affected by challenging global operating conditions.
  • Adjusted EBITDA (US GAAP) -- $1 billion, representing a margin of 4.4% for the quarter.
  • Adjusted Net Income Attributable to JBS -- $167 million, compared to $595 million in the prior year period.
  • Adjusted Earnings Per Share -- $0.16, down from $0.54 in the third quarter of 2025.
  • Net Leverage -- 3.54x, increasing from 2.39x in the prior year due to a more challenging operating environment and lower EBITDA performance.
  • Total Liquidity -- $8.2 billion, supported by $4.1 billion in cash and an increased revolving credit facility of $4.2 billion.
  • JBS Beef North America US GAAP EBITDA -- $21 million, returning to positive profitability as margins improved sequentially from negative 2.9% in July to 3.9% in September.
  • Mexican Cattle Imports -- 1 million head expected on an annualized basis, as heavier cattle reaching processing weights sooner support a more constructive supply outlook.
  • JBS USA Pork Adjusted EBITDA (US GAAP) -- $97 million, reflecting a margin of 5.2% as higher global supply and weaker demand pressured industry pricing.
  • Pilgrim's Pride Adjusted EBITDA (US GAAP) -- $316 million, with a 6.8% margin as profitability was pressured by pork market conditions in Europe and higher input costs.
  • Seara Adjusted EBITDA (US GAAP) -- $255 million, representing a 10.2% margin supported by record poultry export volumes in September.
  • JBS Brazil Adjusted EBITDA (US GAAP) -- $144 million, impacted by lower export volumes to China following the completion of the 2026 quota.
  • JBS Australia Adjusted EBITDA (US GAAP) -- $155 million, as higher cattle and lamb costs driven by consistent rainfall across livestock regions weighed on results.
  • Flora Acquisition -- $542 million enterprise value, involving the payment of $367 million in JBS treasury shares and the assumption of $175 million in debt.
  • CapEx Reduction -- $500 million, representing the planned decrease in capital expenditures for 2027 as management prioritizes deleveraging.
  • Free Cash Flow -- negative $167 million, reflecting a $653 million decline in adjusted EBITDA and higher working capital consumption for grain and poultry inventories.
  • Australian Equity Sale -- $800 million expected in cash proceeds, pending regulatory approval from the Foreign Investment Review Board in Australia.
  • Tax Credits -- $3 billion total, consisting of $800 million in VAT-related credits and $2.2 billion in income tax credits available for monetization.
  • Debt Profile -- 14.4 years average term, with more than 95% of the debt carrying fixed interest rates at an average cost of 5.7%.
  • Just Bare Brand Market Share -- 3 percentage point increase year over year, positioning it as the fastest-growing brand in the frozen fully cooked category.
  • Cash Flow Breakeven -- $5.5 billion in EBITDA expected to achieve breakeven for 2026, incorporating interest expenses of $1.4 billion and capital expenditures of $2.1 billion.

Need a quote from a Motley Fool analyst? Email pr@fool.com

RISKS

  • Batista Filho stated, "Market conditions [for pork] deteriorated rapidly during the quarter. Higher global supply and weaker demand have pressured prices and margins," indicating continued challenges for the segment into the first half of 2027.
  • Cavalcanti stated, "The fourth quarter, we will still have the negative impact of probably a lower fourth quarter than it was the fourth quarter last year," reflecting potential pressure on year-over-year performance despite seasonal improvements.

SUMMARY

JBS N.V. (NYSE:JBS) reported third-quarter performance affected by challenging market conditions across multiple business units, including global pork oversupply and margin pressure in the poultry segment. Management stated that the company achieved a return to positive profitability in the North American beef business, attributing the turnaround to structural changes that integrated fed, regional, and case-ready operations. The company emphasized its multiprotein diversification strategy as a core mechanism for navigating protein-specific industrial cycles and stabilizing long-term earnings. Management reported the acquisition of personal care brand Flora as a strategic move to verticalize byproducts and access new sales channels such as drugstores in Brazil. The company indicated that cash generation and deleveraging are primary objectives, with planned reductions in capital expenditures and anticipated asset sale proceeds expected to improve the net leverage ratio toward a target of below 3x by the end of 2027.

  • CEO Tomazoni stated, "The fourth quarter is also an important period of Seara, supported by strong seasonal demand in the local market," anticipating a recovery in international sales and inventory release.
  • Management stated that the reopening of the U.S. border to Mexican cattle imports is a factor in improving supply dynamics for the North American beef business by adding 1 million head of cattle annually.
  • CFO Cavalcanti noted that the Flora acquisition enables the monetization of significant tax credits while providing access to higher-margin nutrition and health platforms.
  • Management expects to reduce capital expenditures by approximately $500 million in 2027 by postponing new growth projects and focusing on essential maintenance.
  • The company reported that 93% of the tallow consumed by the newly acquired Flora business is already supplied by JBS, demonstrating the verticalization of its byproduct value chain.
  • Management indicated that the Australian business remains stable despite short-term margin pressure from high lamb prices and record rainfall, citing healthy herd levels as a long-term benefit.

INDUSTRY GLOSSARY

  • ICMS: Imposto sobre Circulação de Mercadorias e Serviços; a Brazilian state-level value-added tax that generates credits for exporters.
  • VAT: Value-added tax; a consumption tax placed on a product whenever value is added at each stage of the supply chain.
  • CBS: Contribuição sobre Bens e Serviços; a federal tax proposed under the Brazilian tax reform to replace existing social contributions.
  • IBS: Imposto sobre Bens e Serviços; a state and municipal tax proposed under the Brazilian tax reform.
  • Tallow: A rendered form of beef or mutton fat used in industrial applications such as soap manufacturing and personal care products.
  • Genu-in: A collagen-based health and nutrition platform operated by JBS.
  • Huon: The salmon and aquaculture business unit of JBS in Australia.
  • Friboi+: A retailer relationship program operated by the Friboi beef brand in Brazil to expand domestic sales.
  • Just Bare: A brand of antibiotic-free and organic chicken products under the Pilgrim's Pride portfolio.
  • B2C: Business-to-consumer; a model where products are sold directly to individual consumers rather than to other businesses.
  • CNPJ: Cadastro Nacional da Pessoa Jurídica; the official Brazilian corporate tax identification number used for consolidated tax reporting.

Full Conference Call Transcript

Operator: Good morning, and welcome to JBS' Third Quarter of 2026 Results Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. Any statements eventually made during this conference call in connection with the company business outlook, projections, operating and financial targets and potential growth should be understood as merely forecasts based on the company's management expectations in relation to the future of JBS. Such expectations are highly dependent on the industry and market conditions and therefore, are subject to change. Are present with us today, Gilberto Tomazoni, Global CEO of JBS; Guilherme Cavalcanti, Global CFO of JBS; Wesley Batista Filho, CEO of JBS USA; and Christiane Assis, Investor Relations Director.

Now I'll turn the conference over to Gilberto Tomazoni. Mr. Tomazoni, you may begin your presentation.

Gilberto Tomazoni: Good morning, everyone, and thank you for joining us today. The third quarter was marked by challenging market conditions across several of our businesses, changing international trade flows, pressure on poultry margins, and a global oversupply of pork affected our results. At the same time, we made progress in important areas of our operations, reinforcing our confidence in the strategy we have been executing. Our experience in the food industry has shown us the importance of understanding market cycles, improving efficiency, and making decisions that strengthen our business over the long term. Our important development in the quarter was the return to positive EBITDA in our U.S. beef business.

This is an encouraging result of the work we have been doing to improve competitiveness. There is still more to do, but we are beginning to see the benefit of these initiatives. Wesley will provide more details of the performance of the North America business and the actions underway. Turning to Pilgrim's Pride. As Fabio Sandri highlighted during the company's third quarterearnings call chicken continues to resonate with the consumer across its markets, supported by affordability and the strength of its diversified portfolio. He also emphasizes the progress in operational efficiency, innovation, and investment in high-value products. These remain important priorities as Pilgrim's continues to strengthen its business and build resiliency across market cycles.

In Brazil, despite a challenged quarter, our team responded promptly and adapting production and commercial strategy and leverage our global network and distribution capabilities. While exports to China declined sharply, Friboi successfully redirected volumes to other markets and expanded domestic sales. This performance reflects the strengthening of Friboi brands, the value of our Friboi Plus retail relationship programs, and the effectiveness of our commercial execution. We already see an improvement in October, reflecting this adjustment and renewed demand from China as a customer secured volumes under the 2027 -- '27 quota. Together with seasonality and stronger domestic consumption, this created a more favorable environment for our Brazilian beef business in the fourth quarter.

The recovery in export volumes, combined with the strongest seasonal demand in Brazil, give us confidence in a better fourth quarter for Friboi. Our strong brand, customer relationship, and access to international markets remain important competitive advantages, allowing us to respond to changing in demand and maximize the value of our products. Friboi is a clear example of how strong brands, close relationship with retailers, and access to different markets helped us to respond to challenging conditions and strengthen our competitive position. At Seara, the quarter was affected by higher costs and a more challenging commercial environment in Brazil.

Despite this pressure, Seara gained market share across the categories and reached the highest ever level of brand preference and consumer consideration. These results reflect the strength of the Seara brand and its position with Brazilian consumers. We are focusing on what we can control, improving efficiency and commercial execution, strengthen the integration between our operations and customers, and increasing the value of our portfolio. We continue to invest in automation at Seara to improve productivity and efficiency. Seara's strong brand, innovation, and investment in production capability provide a solid foundation for growth. The gains in market share and record brand indicators reinforce the competitiveness of Seara of the strength of the commercial execution.

Internationally, the Middle East remains as an important market, where our investment in local production and distribution are strengthening our presence and contributing positively to results. In Europe, we maintained production and built inventories during a period of trade restriction, position the business to benefit as sales resume. The fourth quarter is also an important period of Seara, supported by strong seasonal demand in the local market. Together with the recovery in international sales and inventories built during the quarter, this support a more favorable outlook for Seara in the final months of the year. Across the global operation, market conditions vary, but the pace of recovery will not be the same across the proteins and geography.

This reinforced the importance of our diversification strategy. We have built JBS as a global multi-protein company with access to different markets and sources of earnings. Diversification does not eliminate industrial cycles, but it strengthens our ability to navigate them, allocate capital, and continue developing our business. Our investment in efficiency, innovation, brands, and value-added products support this long-term strategy, and our people remain fundamental to the execution with experienced team close to our operations and customers. Cash generation is another important priority. Leverage increased during the quarter as expected, reflecting the operating environment. We remain focused on working capital management and disciplined capital allocation, maintaining the financial flexibility need to be support our investments.

We have built JBS as a long-term vision, investing consistently and strengthening our ability to compete in different markets and industrial cycles. Our strategy remains unchanged. We will continue to focus on execution, efficiency, innovation, and develop our people, creating conditions for sustainable growth and long-term value creation. Our leadership transition is progressing as planned with Wesley Batista Filho gradually take on greater responsibility for JBS operations. This is a natural step in the company evolution, supported by our strong management team, consistent strategy, and our people we have built over the years. Thank you very much. I will now turn the call over to Wesley.

Wesley Batista Filho: Good morning, everyone. The main highlight of the quarter was our U.S. beef business returning to positive Adjusted EBITDA under the U.S. GAAP after 2 challenging years. This reflects both improving market conditions and the operational changes we've been implementing. Earlier this year, we brought our fed beef, regional beef, and case-ready operate business units under 1 management structure to better coordinate procurement, production, and sales and optimize our production footprint. We've also increased our focus on yields, productivity, maintenance, operational reliability, and cost discipline. On the market side, the reopening of the U.S. border to Mexican cattle imports is an important development. Cattle are arriving heavier and reaching processing weight sooner.

We expect approximately 1 million head of imported cattle from Mexico per year. Cattle prices have declined from recent peaks, while beef prices remain resilient. Although cattle supplies remain tight, Mexican imports and a better balance in processing capacity support a more constructive outlook. Turning to U.S. pork. Market conditions deteriorated rapidly during the quarter. Higher global supply and weaker demand have pressured prices and margins. We expect these conditions to remain challenging into the first half of 2027. Our focus is on cost management and operational efficiency. The U.S. has harvested its second largest corn crop on record, supporting ample grains availability and stable feed costs.

In South America, soybean planting in Brazil has progressed within the ideal window, although it is still early to assess the second corn crop. Overall, we're encouraged by the improvement of the U.S. beef business. Our focus remains on what we can control, improving productivity, managing costs, and making our operations more competitive. Thank you, everyone. I will now turn the call over to Guilherme.

Guilherme Cavalcanti: Thank you, Tomazoni and Wesley. Last night, we announced the acquisition of 100% of Flora for the enterprise value of $542 million, of which $367 million for the equity and $175 million in debt assumption. All the equity will be paid in JBS treasury Class A shares. There will be no impact on JBS net leverage given Flora EBITDA. Flora brings higher margins than JBS, a portfolio of well-established home and personal care brands, and significant synergies. Flora also brings an important strategic advantage to JBS.

Its established B2C platform gives us access to new sales channels in Brazil, particularly drugstores and specialized retailers, which we can leverage to accelerate the growth of our higher value-added products, including Genu-in, our collagen-based health and nutrition platform. At the same time, Flora is highly complementary to our value chain as it uses raw materials that JBS already produces. Tallow is a clear example with approximately 93% of Flora's consumption already supplied by JBS. This combination allow us to move closer to the end consumer while creating new avenues of growth. We see cost synergies from integrating corporate and commercial functions as well as additional opportunities across logistics, procurement, and tax.

Considering only 2027 synergies, Flora acquisition multiple would reduce from 7x to less than 4.9x. Over 10 years, we estimate the present value of total synergies and monetization of tax credits at $422 million, further reinforcing the value creation of the transaction. On Page 17 of the 10-Q financial statements, we disclosed approximately $800 million in VAT-related tax credits and $2.2 billion in income tax credit. Additional details, including breakdown, further explanation can be found on Page 18 of our 2025 annual financial statements. Keep in mind, under Brazil's tax reform, VAT tax ICMS will be gradually replaced by CBS and IBS, but we expect the tax credit accumulation to continue to grow.

To establish the synergies, you can use the applicable tax rate, Flora's revenue and net margins, incorporating a higher capacity utilization and additional capacity expected to come online over the next years. We also announced the acquisition of Canal Rural for the enterprise value of $16 million to be paid in JBS treasury Class A shares. Canal Rural brings us closer to the producer, strengthens our ability to advance traceability across our indirect supplier base, and provides an important platform for engaging with society and policymakers. Let's now move on to the operational and financial highlights of the third quarter of 2026. Net sales reached $23 billion for the third quarter.

Adjusted EBITDA under IFRS totaled $1.2 billion with a margin of 5.2% for the quarter. Excluding mark-to-market adjustments on biological assets, adjusted EBITDA margin would have been 5.5%. This metric is used by some of our peers, which also report under IFRS. The main impact was the mark-to-market in U.S. pork given the reduction in the future curve of live hogs. It's important to highlight that there is no cash impact related to that. Adjusted EBITDA in U.S. GAAP totaled $1 billion, which represents a margin of 4.4% for the quarter. Adjusted operating income was $521 million with a margin of 2.3% in IFRS and $597 million in U.S. GAAP with a margin of 2.6%.

Net income was $164 million in the quarter and earnings per share of $0.15. Excluding the non-recurring items, adjusted net income would be $167 million and earnings per share will be $0.16 in the quarter. Free cash flow was negative $167 million in the third quarter with $551 million decrease year-over-year, explained by $653 million decline in adjusted EBITDA and higher working capital consumption in Brazil, particularly inventories. The increase was mainly reflected higher grains inventory at Seara as well as higher chicken inventories at Seara in Europe. The company also faced high inventories in JBS Brazil beef products to be sent to China in the fourth quarter 2026 to fulfill the '27 quota.

This offset the quarterly positive working capital contribution of $325 million positive from the U.S. and Australia business units. Total working capital consumption was $106 million in the quarter. Not considering guidance, but simply updating the increasing the cash flow breakeven EBITDA exercise for the year, we expect $5.5 billion in 2026, driven by $2.1 billion in capital expenditures, working capital, expected consumption of $550 million in 2026, an improvement of $300 million year-over-year, legal settlements of $100 million already realized in 2026, biological assets of $850 million, flat over 2025, interest expenses of $1.4 billion, an increase of $100 million versus the previous estimate due to the higher net debt.

Leasing expense at $500 million in 2026 and an effective tax rate of 25%. Another exercise, again, without providing guidance, is to look at the potential for cash flow generation in 2027. In Beef North America, our largest segment, adjusted EBITDA was negative by $309 million year-to-date in U.S. GAAP. Considering year-to-date working capital consumption of $254 million and capital expenditure of $158 million, the cash consumption of this business unit was $721 million. For every 1% improvement in Beef North America EBITDA margin, this would translate into approximately $300 million in EBITDA. We are still in the budgeting process, but we expect to reduce capital expenditures by around $500 million in 2027.

Considering the closing of Australia's equity sale and cash flow improvement, we expect leverage to be within our target range for the end of 2027. Debt profile. We continue to strengthen our liquidity position. In August, we announced an increase in our revolving credit line from $3.5 billion to $4.2 billion, while reducing the all-in cost of this line. Our cash liquidity combined with the revolving credit line facility totaling approximately $8.2 billion. Our average debt term reached 14.4 years with an average cost of 5.7%. Net leverage ended the quarter at 3.54x. Excluding the mark-to-market of the biological assets, our net leverage would have been 3.41x.

However, the company maintains a well-balanced debt maturity profile with no material maturities over the next 5 years. It is also worth noting that more than 95% of our debt has fixed interest rates, 33% maturing beyond 2050 and all the debt up to 2032 has coupons below the equivalent treasury rates. On August 18, we delivered a proposal to the Board of Pilgrim's Pride Corporation to acquire the shares of PPC common stock that JBS and its affiliates don't already own, as announced to the market. Given our ownership of approximately 82% of PPC and our pending proposal, we will not take any questions related to PPC. We appreciate your understanding.

With that, I would like to open to Q&A session.

Operator: [Operator Instructions] Ladies and gentlemen, our first question comes from Gustavo Troyano with Itaú.

Gustavo Troyano: And my question is on U.S. beef and especially thinking about the profitability levels going forward. I just wanted to hear your thoughts on the pace of the segment's margin recovery as we move into the fourth quarter, especially considering that you disclosed the monthly profitability levels for the segment throughout the third quarter, and it seems that the fourth quarter could be better than what the seasonality would suggest. So I just wanted to hear from you if you think that the third quarter could be a bottom for this cycle when we think about 2027, if this margin should start to recover sequentially from the fourth quarter onwards.

And still on that topic, just to follow up on a point that we discussed in JBS Day a couple of months ago when you mentioned that there were some operational improvements to be delivered in the segment, if these numbers are starting to show off in the third quarter? Or if there's a potential for 2027 to incorporate these operational improvements?

Wesley Batista Filho: So we had a good third quarter in our opinion. It started off actually quite tough, more in line with what the second quarter looked like, and it ended up a lot better. Q4 is usually a little bit of, December could always be a little bit of a surprise. But given how it has started in the first half of Q4 here, we expect that Q4 could be stronger than, should be stronger than Q3. So we're expecting a sequential improvement into Q3 (sic) [ Q4 ] as of right now because, again, we're in the middle of the quarter here, but so far, it looks promising.

And again, when we look into next year, based on a couple of things, based on just the market improving overall, the balance between supply and demand for cattle, we think we're going to have a much better year into next year. And probably, as of right now, we think it's going to be a market that operates in the low single digits, but we could have maybe actually even a positive surprise depending on how things develop. And on top of that, just how the market is going to look like. You said it right. It's a big, big focus of ours is this integration that we are having between our beef business units.

And we're seeing a lot of improvements, but we still expect a lot into next year. I still think that just on operational efficiencies and some more synergies in sales, we could have around or even above 2 percentage points into next year.

Operator: And our next question comes from Mr. Ricardo Alves with MS.

Ricardo Alves: Question on Flora, about 80% coming from taxes. I missed the very beginning of the explanation on the tax credits, Guilherme. Can you go over the tax credits again, just in terms of how much we should expect in the short term, if there's some timing on when you can really monetize those credits? And then when we're thinking about Flora alone, our understanding is that the net debt-to-EBITDA ratio was closer to 4x. So is it fair to say that the leverage was also a factor for the transaction, the leverage at the Flora level?

So I'm not talking about the leverage of JBS, because maybe in terms of short-term financing, given that long-term rates are in a much more difficult place today in Brazil, maybe you incorporate that into the balance sheet of JBS, maybe you're going to be able to leverage more all the growth that you expect in the personal care, all the discussions that we've had in the past around collagen. So just to understand how within the JBS portfolio, how you could accelerate the growth potential you see there, if that was also a rationale for the transaction. So just 2 follow-ups from the Flora transaction, please.

Guilherme Cavalcanti: Okay. Thank you, Ricardo. So beginning with tax credits, the monetization of tax credit is pretty straightforward. As you know, the ICMS, the VAT tax exporters are exempt of that. But we pay ICMS on the inputs in the states we operate. But when you export the product, we cannot offset the ICMS we paid. So this becomes a credit, okay? And those credits at the consolidated balance sheet, are around $800 million in JBS. So when we have Flora inside JBS with the same CNPJ, as we call it the same corporate, we can pay Flora's ICMS on the domestic sales with the own credit or the ICMS credits that we have accumulated, okay?

These ICMS, as I mentioned, will be replaced by CBS and IBS, which will have the same dynamic of credit accumulation. It may be even more. So then we'll be able to use to monetize those credits with Flora, okay? And the last is Flora will start to pay income tax next year. Bear in mind that we have, as I mentioned, $2.2 billion in income tax credit in JBS balance sheet, which we can also be paid to pay Flora's income tax. So basically, those are the major part of the tax credit synergies. As you mentioned, it's the most part of the synergies. Now the net debt to EBITDA, you are putting on the 2026 Flora's EBITDA.

But Flora, some segments of Flora operated in 2026 with 49% capacity, which we expect to increase it, the capacity to 70% next year and so on because we have some disruptions in 2026, factories renovation, things that decreased our capacity utilization. And we have the CapEx, expansion CapEx that is being implemented and new capacities coming online in the next years. So it's, because we have all these downtimes, because we have these disruptions and we have the capacity coming online next year, it's better to look at 2027 EBITDA that is around BRL 420 million, okay, for next year. So considering this BRL 420 million, net debt to EBITDA of Flora would be even lower than JBS.

And as we put more capacity online throughout the years, increasing revenue and EBITDA and monetize tax credit, the net effect on leverage throughout time is even positive with Flora acquisition. Clear, Ricardo? So now let's talk to the strategic part. I'll begin and Wesley will help here.

Wesley Batista Filho: Yes. So what I would say here, Ricardo, is obviously, all of those are the short term, more simple parts of this whole opportunity here. But what we are very interested about is we see this as more of a continuation of the work we've been doing for the past 5 years, especially when we started our business with Genu-in Brazil and with BioTech also in Spain and in the south of Brazil. And we think that the future of the protein market is going to be, obviously, in the center of the plate, that's a big, the main part of, a big part of the business, and that continues to be a main focus of ours.

But we cannot ignore and we need to be very, very much present in all of the nutritional supplements and nutritional part of the business that we think it's a huge value-added part of the business, especially given the production capacity that we have. And we think that starting off in the Brazilian market that we have a lot of strength in the commercial side overall, being able to distribute now with a different, obviously, distribution base for all these dry goods, being able to create a strong B2C business for all of the sort of the nutritional market, we think it's a big opportunity and something that will add a lot of value to our core products.

And on top of that, enhance our portfolio on nutrition overall. So going from the center of the plate also to all of this nutritional side. And again, it's a business that's growing within JBS. And we think that in the future, in the next decade, this will become a huge business globally as a whole, and we want to be an important part of that. So this is the, it's an important step for us to grow in that direction.

Guilherme Cavalcanti: I also would highlight that it's also an important way for us to monetize our byproducts. For example, if you look at Darling, the company in U.S., a great part of its valuation is for the ingredients that enhance human health and well-being.

Operator: And now Mrs. Isabella Simonato would like to ask a question from Bank of America.

Isabella Simonato: So I want to follow up on the Flora deal. I guess the overall rationale is clear, but I wanted to ask if we can think about this acquisition as the first step of some category that can become bigger over time for JBS, right? I recall we had the discussion, I think, in the first JBS Day in the U.S., right, if you could move away from proteins and diversify and become more of a consumer goods, right, company. So I wonder if we can interpret this move as something, as a first step of something bigger, right? I guess that's my first question.

And still on that matter, right, when we compare Flora to eventually other targets of acquisitions in that segment, right, if you could just give us a context about their peers, right, and eventually relative valuation and why do this now, right? My sense is that the implementation of the tax reform also matters and timing, but I just want to give, to understand a little bit better timing and the context for this. And I understand that there is no immediate balance sheet impact to JBS. But I wonder if adding complexity here and eventually any type of additional investments that Flora might require in this time, if that makes sense?

Wesley Batista Filho: Isabella, so I'll start here. Obviously, our, like I said, it's -- this part of nutrition and being able to develop a strong B2C business for all this supplement category is a main target of ours, and it's one of the biggest parts of the vision of this acquisition on top of all the things that Guilherme mentioned that are very important as well from an integration and synergy perspective, verticalization as well of our core products. Obviously, we're also going to, it's very important for us to grow all of this to have a complete portfolio. And so we're going to have other portfolios that we are entering as a company right now.

And obviously, we're going to do everything we can to be very successful in that and to have a leadership position in those categories within the Brazilian market. And obviously, we'll see what the future holds for that. So if there is accretive ways to grow that business within the Brazilian context as of right now, it's something that we're going to evaluate. But again, we think that there is potential. So let's see. I'll let Guilherme mention here about the valuation.

Guilherme Cavalcanti: Isabella, so we have to split in 2 fronts here. So if you look at the international peers, enterprise value to EBITDA for 2007 (sic) [ 2027 ] multiple ranges from 10x to 14x. But if you look at the Brazilian comparables, these range from 5 to 10x. So in Brazil, multiples are lower than our international peers. But we think that we have potential. That's one of the reasons that we have, we see potential value creation. And again, and as I mentioned, if you look at all the synergies and put the net present value of them compared to the enterprise value we paid, we see that the multiple is very, very compelling.

Operator: And our next question comes from Mr. Henrique Brustolin from BBI.

Henrique Brustolin: My question is back to U.S. beef, especially about Mexican cattle imports, right, that Wesley, you have mentioned, right, the relevance of cattle imports from Mexico to help rebalance the U.S. industry. We are seeing imports growing, but still at a somewhat slow pace, right, to get to the 1 million heads per year. And of course, there is a natural ramp-up here. But it would be great to get your view in terms of how are imports right now shaping up relative to your expectations and how you expect the pace picking up going into 2027, so we can see this better environment in terms of cattle supply and beef margins.

Wesley Batista Filho: We think that Mexico, obviously, when it first opened and you just had one port of entry was below 1,000 heads, beginning 1,000 heads per day. But given the volumes that are crossing as of right now, we think it's very relevant. We, obviously, there's many variables here. And, but given what we know right now, we would expect into an annualized basis of about 1 million head. If you think that we have, I mean the 2 biggest states of Mexico, right, being open to export to the U.S. And you're doing 1 million head out of the 1.2 million that used to come. I think it's pretty, I mean, it's pretty relevant.

I mean, and it's a big deal. If you think about it also, I think it's a good way to think about it is in the past, again, Mexican cattle would account for 4% to 5% of the U.S. processing volumes. But if you look at just what that percentage was of the Southern states, you're talking about, I don't know, probably 15, around 15% of the processing capacity of the south of the southern plants. So it's a big deal and just the amount of cattle that's been crossing, it's relevant enough to make a big difference.

And I attribute a lot of the improvement in the cattle situation for us in the U.S. coming from the reopening of the Mexico border.

Operator: And now Mr. Pooran Sharma from Stephens has a question.

Pooran Sharma: Just wanted to focus on U.S. pork. My first question would be to understand the commentary you alluded to earlier. I believe you said you expected maybe some potential relief in the first half of '27 or at least do you expect the conditions to drag on through the first half of '27. Just wanted to see what gives you confidence or visibility into improvement in the back half of 2027. And for my follow-up, I wanted to understand just the differences between U.S. GAAP and IFRS a little bit better for this segment. We've seen the last few quarters a big divergence in these margins. And I think it's largely due to the biological asset valuation.

Given the move we've seen in lean hogs in 4Q, I just wanted to get a sense if you would expect the same type of divergences between U.S. GAAP and IFRS to persist in 4Q for U.S. pork.

Wesley Batista Filho: So on the pork side, we expect that it will continue to be tough, at least through the first half of next year. What we expect, and we see the USDA number for just global production kind of similar in line with what we believe is we think that there is going to be an adjustment of production globally. Obviously, countries that are more competitive and more productive are going to gain a bigger market share of the global pork supply and countries that are less efficient are going to lose those space and competitiveness. So the USDA is showing a decrease in next year's pork production globally, similar to the increase we had this year.

We already see numbers, for example, in China, which are the biggest pork producers in the world, reducing, they used to hover around 40 million sows. That was their total herd there of sows. And now they are close to 36 million, and that's almost, it's a relevant increase -- decrease, excuse me, in a very, very large country. And we think we're going to see that in other areas, countries that are less competitive are going to lose pace in the market. And I think that globally, overall, we're going to see an adjustment. Obviously, you have to remember that the pork cycle is a lot shorter than the beef cycle.

So I'm not saying that the beginning of second half of next year, it's going to be great and things are going to be completely changed. I don't know that yet. But our expectation is that given what we're seeing globally in, especially in some of these countries moving to reduce production, we think that there is a good chance that we have a better second half of next year.

Guilherme Cavalcanti: Okay. Going to the mark-to-market, you are totally right. The volatility all comes from the fact that the IFRS inventories are mark-to-market, including the hogs, while in U.S. GAAP is at cost. And how it's the mark-to-market, we get all the future curve of hogs to price our inventories. And that's what the big swing was. So looking at the fourth quarter, it will depend on this future curve. We think that the future curve is already inclined. So only if it inclines even more down, that would have another effect like that.

But it's worth mentioning that, for example, WH, which reports in IFRS and because of this hog volatility, its EBITDA adjusted, is adjusted for the mark-to-market of biological assets.

Operator: And next is Mr. Thiago Duarte with BTG.

Thiago Duarte: I wanted to circle back to Guilherme's exercise in the end of the presentation, particularly when discussing the outlook for 2027. And obviously, you never provided a guidance, but looking at the exercise and trying to reconcile the numbers a little bit, you talked Guilherme about coming into the end of 2027 with the leverage of the company within what you call the safety zone, if I'm not mistaken, which is up to 3x leverage, right? And as we try to sort of reconcile the numbers to your EBITDA, the way I'm looking at the math here, it implies a pretty nice improvement in the company's EBITDA into 2027 relative to 2026.

And my understanding is that the biggest contributor to that in your exercise has to come from the U.S. Beef division. So my question to you guys and obviously, going back into the discussions about cattle imports from Mexico and so on and so on is, are you comfortable that U.S. beef can approach the sort of historical normalized of low to mid-single-digit margin into 2027. So that would be the question trying to reconcile to the exercise that Guilherme did in the end of the presentation.

Guilherme Cavalcanti: Okay. Thank you, Thiago. Yes. I also read your report last night. So, and you mentioned that at the $1.4 billion EBITDA of the fourth quarter, we would be ending at 3.75x. That's not correct. You forgot the free cash flow generation of the fourth quarter, which kind of sets (offsets) part of the decrease in the last 12 months EBITDA. Bear in mind that the last quarter, we have the deferred livestock, we will have the inventory sales in Europe of Seara, and we have the resume of Chinese purchase from the working capital we consume in JBS Brazil in the fourth quarter.

So therefore, with the $1.4 billion EBITDA that you mentioned for the fourth quarter, we would be ending between 3.5x and 3.55x net debt to EBITDA, depending on, of course, the free cash flow, but that's, I think it's a better estimate. So now for the next year, you're right, the main assumption here is the turnaround of U.S. Beef. Remember, this year, U.S. Beef consumed $721 million of free cash flow already because working, only working capital was $254 million and $310 million of EBITDA. So for next year, if this EBITDA comes to the positive side, so whatever, that's why I mentioned each 1% is $300 million EBITDA.

And the working capital consumption was mainly due to the cattle prices increase in the first semester. If we think of falling cattle price or even a stable cattle prices, we should release working capital from this business unit instead of consuming working capital. So my assumption for next year, again, bear in mind, we have the Australia equity sale of $800 million cash inflow. We have the fourth quarter, as I mentioned, free cash flow generation. And for next year, if we have a turnaround in the Beef segment and we end up with an EBITDA between $5.5 billion or $6 billion, we will be below 3x.

Operator: And our next question comes from Mr. Benjamin Theurer with Barclays.

Benjamin Theurer: Actually, I would like to pick up on that, on the exercise and one of the commentary you make as it relates to CapEx next year. So if I picked it up the right way, I think you said you're looking into the budgeting to reduce CapEx by approximately $500 million. Is that against the roughly $2 billion base in 2026? And if so, what would be areas where you're looking at in terms of cutting CapEx? Is that cut outright? Or is that postponing? How should we think about that reduction in CapEx that you've mentioned?

Guilherme Cavalcanti: That's a very important point that I also forgot to put in the equation of the previous question that also I embedded around $500 million of capital expenditure decrease for next year, improving free cash flow. Our $2 billion free cash flow, $2.1 billion of this year, bear in mind that around $1 billion in maintenance CapEx, there's not much change of that. But $1 billion is growth CapEx.

So what we'll be doing for next year is that some CapEx that, some projects that we started, we already began and so we'll finish it, but we will not start new projects or the ones that didn't start, we will postpone for the other year or depending on how the year stays. So that's why we are still in the budgeting process. In fact, I'm going to Greeley next Friday to, for budget and CapEx meetings, but we are very confident that we can cut around $500 million of CapEx. Remember that in 2023, when our EBITDA was $3.5 billion, we budgeted $1 billion maintenance CapEx for 2024 and a $300 million growth CapEx for 2024.

But because 2024 was better than expected, in fact, we ended up with $6.8 billion in EBITDA and $2.8 billion of free cash flow. We then we restarted some projects, and we end up 2024 spending $500 million in growth CapEx. So that's what we intend to do. We will stop postpone CapEx, reduce the $500 million. If the year is better than expected, we can anticipate the ones that we postponed.

Benjamin Theurer: It's clear.

Operator: And our next question comes from Mr. Thiago Bortoluci with GS.

Thiago Bortoluci: I think my question is for Wesley, right? And I'd like to stress again the demand side in the U.S., right? And this is just to put in perspective a few of the information we have so far. We know pork has been under pressure for a while. It's not the first time you mentioned it in your press release. When I see the numbers for Pilgrim's, you continue to allude to strong demand. But then when I see top line growth, it's pressured within foodservice, fresh and retail.

And then I think more importantly, when I see the evolution of the cutout for beef, throughout the grilling season, it moved actually downwards and ended the quarter even a little bit below last year, right? So in a context when we have rates in the U.S. potentially higher for longer, inflation potentially higher, how confident you are that demand will remain sticky into next year? And more importantly, how confident you are in your pricing power eventually to protect or even expand margins in this context?

Wesley Batista Filho: Thanks, Thiago. So look, we see demand for protein in general has been pretty strong. I think the fundamentals are all there. I don't want to be too repetitive and talk about all of them because it's something that in all conferences and all meetings, we all talk a lot about and we all kind of see similar fundamental trends that everybody knows. But when we look at specifically per protein, we see beef demand. When you have such a big increase in prices, obviously, our price follows the price of cattle.

So when we had such a large increase of cattle prices and then you have such a large increase of cattle of beef prices, sometimes it's even difficult to look at the seasonality because just maybe the price of cattle goes up in the off-season kind of period, right, and then things kind of stabilize after. So it's always a little bit tricky to look at that in that way. But what we actually, the way I would say it is having a cutout that's in the high 300s and still have the strong volume that we're seeing, I think that's a big deal and it shows that demand in beef is really strong.

And when we talk to customers, we hear that the beef demand is quite inelastic. And actually, I would even say, Thiago, much more inelastic than we even expected before all of this big shortage of cattle that we've had in the U.S. In chicken, we're seeing, just in the worldwide, we're seeing the same thing. We're seeing demand for chicken pretty strong, especially in foodservice, and we're seeing a lot of food service chains, QSRs, all going into chicken. So there is a big trend going there. Now obviously, inflation overall across the board, especially in fuel have taken a toll in consumers.

And what we are seeing is that the protein that has had the toughest, the biggest challenge has been pork. Pork absolutely has had the biggest, we're seeing the softness in demand very concentrated in pork. And I think it's, it just shows, I think it's not necessarily anything against pork that the consumer has. It's just that their preference for beef and chicken has been just so strong that the protein that they have, whenever they're in a, they have to stretch a little bit more of their dollar, they're still going to have their beef. They're still going to consume chicken and maybe they cut back a little bit on pork. So that's what we've been seeing.

But overall, the trends are still pretty consistent in our opinion. Having said that, obviously, when overall inflation is just that high and strong and puts a strain in consumers, they have to make a choice, and they have made a choice to cut back on pork demand.

Operator: And our next question comes from Mr. Andrew Strelzik with Bank of Montreal.

Andrew Strelzik: I wanted to ask about Seara. You talked about record chicken exports out of Brazil, but there were also some areas of weakness as well and the margins were the lowest we've seen in a little while. So I'm curious if we should anticipate Seara margins continuing to decline year-over-year in the fourth quarter and into '27 or if you see opportunities for that to recover? And if you do see opportunities for that to recover, what the drivers would be?

Gilberto Tomazoni: Thank you for your question. We see, first, I will be answered direct to your question. See, we see improvement on the margin of Seara for the fourth quarter compared to the third quarter. And what is the reason for that? First, I think, is one of the very important reasons is the appreciation of the dollar against real. And Seara exports 50% of its revenue, and this means a lot in terms of impact in the bottom line. This is the first. The second point that the market for the chicken, just to add the explanation of Wesley, we see the demand of chicken globally very strong.

Seara reported was the largest volume that sold in 1 quarter to export means that the market is very demanding. This is the point that demand is strong and dollar is higher. And there is another point of Seara. In Europe, our team anticipated the restriction of Brazilian poultry export and shipped chicken breast ahead of those restrictions, building inventories in this region. We expect to sell these inventories in the fourth quarter, allow us to serve customers even while shipment from Brazil were restricted. Together with the stronger seasonal demand in Brazil and support the favorable outlook of Seara for this month, we really expect higher margin than the third quarter of Seara.

Operator: And our next question comes from Mr. Leonardo Alencar with XP.

Leonardo Alencar: Probably a follow-up on the last question. I understand there are many moving parts going on in Brazil right now. So with the Newcastle in Santa Catarina and now the restriction on pork exports to Philippines, but also this inventory buildup because of the Chinese quota for beef and Seara's strategy on corn, and there are too many things in place to get a better view on the Q4. If you could just walk us through on this inventory release I would expect probably beef and part of this chicken in Europe to be released on Q4, but then corn, maybe it would stay for longer. But then this impact on exports, how they could play on margins as well.

So just some more color on that. Did you hear my question? I'm not listening anything from your side.

Wesley Batista Filho: Sorry, Leonardo. I think Tomazoni had a problem there with the...

Gilberto Tomazoni: Sorry. Sorry, I'm back. Sorry.

Leonardo Alencar: Did you get my question?

Gilberto Tomazoni: Yes. I think I got your question. Let me see if I will start to answer about the... You hear me, Leonardo?

Leonardo Alencar: Yes.

Gilberto Tomazoni: Okay. Just to talk about, you mentioned the restriction that we have in terms of Philippines. We do not yet know certain what is the restriction will be. There is a talk that halting imports for at least 60 days. It is unclear whether this refer to stopping to issuance of import license or halting shipments. If the decision of concerns import license, the impact will be not felt until around January. If the decision is to halting shipments, that impact will be immediately. Of course, we, this will be impact. We not know how is the impact yet. But you know that pork is under pressure globally, as we have mentioned that it's not just in U.S., globally.

And of course, we have market to sell with a lower price that will be impact of margin. But pork is really, if you consider all of the revenue of Seara, pork is the fresh pork is, have a lower impact if you compare the other business that we have in Seara. The other point that you mentioned is about, I think it's about the quota of China. I think it's important that to let know that we start begin production for Chinese market in the second half of September, anticipated this revenue demand under the 2027 quota. That production effort started in the third quarter, while the related sales, we are expected to benefit in the fourth quarter.

We already seen improvement in October. And we are, I think we'll be in an additional revenue that we produced in September, the second half, we just had the cost of the production and not the revenue. Now we are starting to ship to China that we see the strong improvements on results of Friboi in Brazil. And the same will be with Seara. I mentioned before the other question, I think was Andrew asking about the product that we have in Europe. Europe is close. We are selling the product.

We are expecting that we resume the importation on next year or end of this year, but the product will be around in Europe next year, means that I think the strategy we have done both in Seara to build inventory in Europe and the strategy to start to produce early to China in Friboi will be benefit our business in the fourth quarter.

Operator: And our next question comes from Mr. Matheus Enfeldt with UBS.

Matheus Enfeldt: I want to have a question on U.S. beef. We saw peers partnering with cattle suppliers for a while now, but particularly more recently. And we discussed in the past whether the current U.S. cattle cycle is going to lead to a structurally different supply. So my question is more on your end. If you're, what's the way to get closer to the rancher if there are any alternatives there, anything that the company is considering or starting the direction? Or if you want to restate the comments from previous calls that it's a business that it's a bit too different from yours.

So trying to understand how you get closer to the rancher if that's a strategy that JBS could also follow.

Wesley Batista Filho: So, no. We see that us entering the ranching business or even the feedlot business is not our focus. It's not our core. It's not something that we are, we've done that in the past. And I think that our model today, which is to partner up with having long-term commitments with companies that are specialized to do that is the best scenario for us, and we don't see ourselves verticalizing the supply chain in beef. We don't see that as something that goes well. Having said that, obviously, we have a very, very strong partnership with a lot of different suppliers.

And those are very long-term agreements that are great partnerships, and we see us having that going in the future, not us doing it ourselves.

Operator: And our next question is from Mr. Lucas Ferreira with JPMorgan.

Lucas Ferreira: I also have a follow-up on the U.S. beef business, which is looking at 2027, obviously, we're going to have more cattle from Mexico and with the ramp-up that we've been seeing is looking great. But on the other hand, we also expect retentions to increase, right? That's the expectation for some normalization ahead. And we started to see some announcements of more capacity being added back to the system. I wanted to hear also on the labor side, if there could be more labor available next year. So the question is really how do you see the net-net of this thing?

So more cattle from Mexico, you mentioned 1 million heads, but eventually more retention and also more capacity being added or more shifts being added as these animals getting into the system. So Wesley, what do you see the net-net of the cattle availability in the country? And if you think there is a risk of more supply actually ends up limiting the upside for margins?

Wesley Batista Filho: Our analysis on beef has always been with the information we have in the public. So we, I'm not going to talk about individual kind of announcements by our peers, but recent announcement nowadays was, I think, a little bit of a continuation of what we heard in the past. So we don't see like there is any news, any new information that changes the way we see the market going forward. We already expected that there, at least there is nothing new from recent announcements from our point of view. It's more of a continuation of what had previously been announced. So we, all of these comments that we're making is based on that as an assumption.

So we think that next year will be, again, a much better supply demand for cattle. And labor hasn't been a problem, at least from our perspective, for a few years now. So even if there is more labor in next year, I don't think it changes. It's something that has already been the case for this year.

Operator: And our next question comes from Mrs. Heather Jones with Heather Jones Research.

Heather Jones: My question is related to the U.S. pork business, specifically on the GAAP results. It was a sharper than expected sequential deterioration. And just trying to get a sense of was that predominantly driven by lower hog production earnings or more evenly split between raising and the processing side?

Wesley Batista Filho: We had a sharp decline in hog producing for sure, and hog producing has been a big part of, it has been doing great for the past years and it has been a great part of a good help to our business and now has been deteriorating more faster. So it's an important part of the decline. So yes, it's an important part of it. But also just overall, spreads have been tighter, right? If you look at spread between cost and hog costs and even hog cost has been kind of compressed on both sides.

Operator: And our next question comes from Mr. Guilherme Palhares with Santander.

Guilherme Palhares: A question here for Guilherme. Guilherme, if you could just recap a bit the steps towards the closing of the Danantara deal, when we should see the $800 million flowing through the balance sheet and just the overall step-by-step until there.

Guilherme Cavalcanti: Thanks, Guilherme. Yes, this depends on the regulatory authorities of Australia, including FIRB. Generally, it doesn't take so long, but it's something that is out of our control. But we don't expect to take a long time.

Operator: And next, we have Mr. Ricardo Boiati from Safra. May have some issues with his line there. So we'll go ahead to the next one, which comes from Priya Ohri-Gupta with Barclays.

Priya Ohri-Gupta: Guilherme, I was just wondering if we could dig a little bit into the leverage discussion. So should we now be expecting fourth quarter leverage or year-end '26 leverage to be similar to where we are now? And how does that sort of dovetail with some of the stronger free cash flow given the working capital unlock in fourth quarter that's expected? And then as we think about the leverage progression into '27, I think you talked a little bit about sort of the EBITDA improvement that could be needed to get you below 3x. But should we be thinking of any potential for debt paydown or any possible refinancing activity that could accompany this?

Guilherme Cavalcanti: Thank you, Priya. So basically, the fourth quarter, we will still have the negative impact of probably a lower fourth quarter than it was the fourth quarter last year. But again, this is always a quarter that we generate a lot of free cash flow. One of the reasons is the deferred livestock, okay? We postponed payments for the next year as a request of the, by the producers. But this year, we also have again, as we mentioned, we produced beef in Brazil in September, but we couldn't sell because of the quotas to China. But in October, we resumed to sell the 2027 quota.

So this is also released and also the Seara chicken inventories in Europe, as I mentioned. So all this together, we think that the free cash flow in the fourth quarter may kind of offset this statistical last 12-month effect, and we finished this year with the levels around where we are now. So for next year, then generally, first quarter is a quarter that we consume free cash flow, mainly because of the postponement of the livestock deferral. But this year, again, we may have 2 effects that maybe also offset this. First is working, better working capital if the cattle prices stays as it is right now, we'll be releasing working capital in the first quarter.

And also the EBITDA, bear in mind that the beef EBITDA in the first quarter this year was negative. And if now we turn around for the positive side, we will have the opposite statistical effect. So if that, maybe we will start deleverage even in the first quarter and getting to the year-end below 3x. But again, some moving pieces here, but I think that the statistical effect should work in our favor next year.

Priya Ohri-Gupta: And how should we think about the debt movement just on the back of that?

Guilherme Cavalcanti: Okay. Sorry. Yes. No, again, remember, we don't, we have short-term debt that is mainly trade finance that is very easy to roll over and cheap as well. And for the next 5 years, we don't have any significant maturity. And up to 2032, all the coupons are below treasury. So again, and with the increase in treasury, that's a few opportunities for liability management, given we have some '34s with 6.75% coupon, that's the ones that in JBS and PPC. That's the only one that I would say that would be more expensive to than what it would be to refinance today. So for liability management today, again, given the treasury curves, there's not much opportunities.

And again, we want to deleverage. And as we generate free cash flow and with the incoming of the Australia equity sale, we'll have to look at some debt to be paid. Probably the first ones will be the Flora's debt that we, or the debt assumption. That is the $150, $160 million debt that we assumed with the Flora deal. Those debt are more expensive than JBS. They are capital markets debt, but they are more expensive than JBS. So probably those ones will be the first to be paid. Then I would say the short-term debt, the trade finance would be the second on the list to be paid.

And I don't see much opportunity for bond repurchase besides those high coupons that I mentioned.

Operator: And our next question, we will go to Ricardo Boiati with Safra.

Ricardo Boiati: Regarding on Australia, do you expect a rebound in exports already in Q4? Or should we look to shipments to fulfill next year's quota to be more concentrated in Q1 2027 in Australia. October was impacted by rains, right? How are you seeing November and December turning out to be there? So I'm trying to understand how to think about sales and margins in Australia at Q4 and in 2027.

Wesley Batista Filho: Yes, Ricardo. So we expect Australia to be stable, somewhat stable here into Q4. Like you said, still raining quite a lot. It's incredible what's been going on in Australia with, in terms of rainfall. It's been, I don't know, probably 5, 6 years that there has been above-average rains in Australia, and we haven't, as long as, I mean, as far as we've been in Australia, we haven't seen such a long period of time with such consistent rains for such a long time. So that's kind of obviously surprising to all of us, and we expected it obviously to be a little bit more on the drier side at some point.

But, so we, in the fourth quarter, we still see quite a lot of rain in Australia. So if anything, we're going to see, if we see an improvement, we're going to see in 2027, not right now. But on the other hand, we see it relatively stable. It's been challenging on the beef side because of this. On the long term, it's actually pretty good news. I mean there is a lot of cattle in Australia. The herd is on a healthy side. All of this rain obviously has a long-term effect that should create a more stable business for us in the future, we think. So in the long run, it's not bad that it's raining that much.

It's actually good news, and we want good weather for raising livestock. Obviously, it creates a short-term pinch that we didn't expect. So, but we're expecting that it should create a longer, more smooth cycle into the future than ups and downs that we've seen in other markets. So because of such a consistent weather. Also, I'll mention that in Australia, we've been able to build quite a lot of businesses that are able to complement. Even though beef is in a challenging moment right now, we have other businesses that we've invested in the last years that are able to bring the average of the whole business actually higher and create a good business.

We're very excited about the business in Australia. We think that our business in Australia is one of our stronger businesses within the company. And we think we're going to have a more stable business in the future because of all this good weather that we're seeing.

Operator: And our next question comes from Mrs. Carla Casella with JPMorgan. Sorry, Mrs. Casella, if you're speaking, you may be on mute.

Carla Casella: Sorry, can you hear me now?

Operator: There you go. Perfect.

Carla Casella: Yes. My question is on M&A opportunities. I was a little surprised by M&A just given how high the leverage is now, recognizing that even the M&A was not adding to leverage. But was there a timing issue to do Flora now? Is it better to do now versus later? I'm wondering what the catalyst was there. And then also, while leverage is higher, are you still looking? Are there more M&A, potential M&A opportunities? And kind of how are you looking at that today?

Guilherme Cavalcanti: Thanks, Carla. As you mentioned, the Flora deal was, the equity was all paid in shares. We assuming $175 million in debt only, and it's bringing EBITDA. The rationale to do now, as I mentioned, is that we have, as I mentioned in the beginning, $800 million in VAT tax credits and $2.2 billion in income tax credits. So those credits, the faster you use it, you monetize it, the better. So bringing Flora now, it's a way to fast monetize the VAT credits also in light of the Brazilian tax reform. So that's the reason why to do now besides, again, the rationale, the strategic rationale that was mentioned.

And as I mentioned, a great part of the valuation and the potential of Darling company is the ingredients to health and nutrition is something that we want to go more and more with our byproducts and be closer to customer and get those high margins. Now for general M&A, I see only very, we have, we just have the closing of the Oman deal, which is $150 million outflow. We have the sale of the Australia, it's $800 million inflow. I don't see any M&A that we would be using cash, maybe only very small M&As, any M&A to a certain size only if the seller accepts to receive JBS shares, which generally very rare cases.

But again, M&A, I would say, on some size, only if the seller accepts to JBS shares, which is generally very rare cases that this happens. So we are not seeing M&As in the radar in the short term because we will be focusing really on deleveraging.

Operator: Ladies and gentlemen, there being no further questions, I would like to pass the floor to Mr. Gilberto Tomazoni and Mr. Wesley Batista Filho.

Gilberto Tomazoni: Thank you. To wrap up, this quarter showed the strength of our diversified global platform and the progress we are making across our business. The return to the positive EBITDA in U.S. beef was an important milestone. We know there is more work ahead, and we remain focused on operational excellence, financial discipline and creating long-term value. I want to thank our teams around the world for their hard work and dedication. Their commitment and execution make this progress possible. And to everyone joining us today, thank you for your time, your continued interest in JBS and your engagement. We look forward to continue to our dialogue. Thank you, everyone.

Operator: This is the end of the conference call held by JBS. Thank you very much for your participation. Have a nice day.

Should you buy stock in Jbs right now?

Before you buy stock in Jbs, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Jbs wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $344,878!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,097,846!*

Now, it’s worth noting Stock Advisor’s total average return is 852% — a market-crushing outperformance compared to 208% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.

See the 10 stocks »

*Stock Advisor returns as of November 10, 2026.

This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. Parts of this article were created using Large Language Models (LLMs) based on The Motley Fool's insights and investing approach. It has been reviewed by our AI quality control systems. Since LLMs cannot (currently) own stocks, it has no positions in any of the stocks mentioned. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company's SEC filings. Please see our Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability.

The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

The Motley Fool
Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. The company's name was taken from Shakespeare, whose wise fools both instructed and amused, and could speak the truth to the king -- without getting their heads lopped off.
Visit Fool.com for more market news More articles by this source

Tags

Stocks Mentioned

Latest Articles

Data is currently not available